NUAK2:  an emerging acral melanoma oncogene

Takeshi Namiki; Sergio G. Coelho; Vincent J. Hearing

doi:10.18632/oncotarget.325

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

NUAK2: an emerging acral melanoma oncogene

Takeshi Namiki, Sergio G. Coelho and Vincent J. Hearing _

PDF | HTML | How to cite

Oncotarget. 2011; 2:695-704. https://doi.org/10.18632/oncotarget.325

Metrics: PDF 3407 views | HTML 3580 views | ?

Abstract

Takeshi Namiki^1,2, Sergio G. Coelho¹, Vincent J. Hearing¹

¹Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20814, USA

²Department of Dermatology, Yokohama Minato Red Cross Hospital, Yokohama, Kanagawa 231-0801, Japan

Received: September 9, 2011; Accepted: September 10, 2011; Published: September 10, 2011;

Keywords: NUAK2, acral melanoma, migration, metastasis, oncogene

Correspondence:

Dr. Takeshi Namiki, email:

Abstract

Recent technological advances in cancer genomics make it possible to dissect complicated genomic aberrations of melanomas. In particular, several specific genomic aberrations including 11q13 amplification and KIT aberrations have been identified in acral melanomas. We recently identified NUAK2 at 1q32 as a promising oncogene in acral melanomas and reported its significant roles in tumorigenesis in melanoma cells using both in vitro and in vivo analyses. NUAK2 as a member of the AMPK family has several intriguing aspects both as an oncogene and as a tumor suppressor gene. Here we review genomic aberrations of melanomas focusing on acral melanomas to emphasize the possible roles of NUAK2 in tumorigenesis in general and suggest that NUAK2 has pivotal roles in acral melanomagenesis.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 325

Publication Alerts

Research Perspectives:

NUAK2: an emerging acral melanoma oncogene

Abstract